Propranolol’s effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis

Michelle H. Lonergan, BA; Lening A. Olivera-Figueroa, PsyD; Roger K. Pitman, MD; Alain Brunet, PhD

Lonergan, Brunet — Department of Psychiatry, McGill University, and Douglas Mental Health University Institute, Montréal, Que., Canada; Olivera-Figueroa — Department of Psychiatry, Yale School of Medicine, and US Department of Veterans Affairs, West Haven, Conn., USA; Pitman — Department of Psychiatry, Harvard Medical School, Charlestown, Mass., USA.

Introduction

It is well demonstrated that emotion enhances memory encoding and facilitates later recall.1 Such observations have important implications in the realm of psychopathology because many disorders have at their core an overly powerful emotional memory, often stemming from a negative life event. For instance, in order for posttraumatic stress disorder (PTSD) to develop, one must experience a life threat accompanied by peritraumatic distress.2 During trauma exposure, endogenous stress hormones (i.e., noradrenaline) overconsolidate the traumatic memory.2 This memory is subsequently reactivated too easily by contextual cues, thereby eliciting strong conditioned emotional responses3 as well as hypervigilance and avoidance of trauma reminders.

Numerous psychiatric disorders also have at their core a negative and sometimes traumatic emotional memory. Trauma exposure is known to increase the risk for other disorders, such as phobias, addiction, depression, panic disorder and obsessive–compulsive disorder.4–7 Negative life events of
leaving short-term memory intact. Propranolol is one of several classes of protein synthesis inhibitors that have been used in animal studies to reduce the saliency of emotional memories. A recent neuroimaging study revealed altered amygdala and hippocampus activity associated with propranolol-induced emotional memory impairment in healthy individuals.

Propranolol is a synthetic β-adrenergic receptor blocker that crosses the blood–brain barrier and exerts peripheral effects on the noradrenergic system as well as central (inhibitory) effects on protein synthesis. Protein synthesis is necessary to consolidate new learning to long-term memory storage. Animal studies have shown that infusing a protein synthesis inhibitor in the amygdala within the time-limited consolidation window leads to a subsequent memory impairment in a fear conditioning task.

Protein synthesis is also required de novo for memory reconsolidation; postretrieval infusions of a protein synthesis inhibitor led to memory impairment of long-term memory, leaving short-term memory intact. Propranolol is one of several protein synthesis inhibitors that have been used in animal studies to reduce the saliency of emotional memories. A recent neuroimaging study revealed altered amygdala and hippocampus activity associated with propranolol-induced emotional memory impairment in healthy individuals.

Propranolol is commonly used to treat migraine, tachycardia and performance anxiety. It is also indicated as a second-line therapy for anxious states because of its effects on the noradrenergic system.

To help determine whether consolidation and reconsolidation blockade using propranolol has any potential as a psychotherapeutic approach for treating mental disorders that have at their core an emotional memory, we conducted a meta-analysis of the experimental protocols involving healthy individuals. We predicted that, compared with placebo, propranolol taken before (or ideally, immediately after) memory consolidation would reduce subsequent recall for negatively valenced material. We made a similar prediction for reconsolidation.

Methods

Inclusion criteria

Studies involving the recall of negatively valenced material in healthy adults published in any language were included if they randomly assigned participants to at least 1 propranolol and 1 placebo group. We limited our search to articles published after that of Cahill and colleagues (i.e., between January 1995 and February 2012). We searched for unpublished studies by combing through abstracts from the conferences of the following organizations: Society of Biological Psychiatry, International Society for Traumatic Stress Studies, American College of Neuropsychopharmacology and Society for Neuroscience. We also contacted authors of included studies, other experts in the field, and investigators with studies registered on www.clinicaltrials.gov.

We found 10 studies using propranolol in PTSD populations: 4 examined consolidation blockade, 2 examined reconsolidation blockade, and the remaining 4 used propranolol for other unrelated purposes. Owing to insufficient numbers and clinical heterogeneity, we could not include studies focusing on consolidation or reconsolidation blockade as a treatment for PTSD in this meta-analysis.

Included experimental paradigms

Memory consolidation

To assess memory consolidation, studies have largely replicated the paradigm of Cahill and colleagues. In this protocol, participants watch a series of slides accompanied by either an emotionally upsetting or neutral verbal narrative for the middle section of the story (slides 5–8). In the emotionally upsetting version, a young boy is hit by a car and rushed in critical condition to the hospital, where doctors frantically operate to reattach his severed legs. In the neutral version, the young boy witnesses a routine hospital drill performed on a dummy at his father’s workplace. Propranolol (or placebo) is typically administered 60–90 minutes before viewing the slides so that when memory consolidation begins (i.e., immediately after viewing the slides), propranolol is at its peak plasma concentration. Memory for the viewed material is tested in a surprise forced-choice quiz after a washout period of 1–7 days.

Memory reconsolidation

The protocols used in reconsolidation studies consist of fear conditioning, script-driven imagery and/or declarative memory tasks. Although fear conditioning and declarative memory...
tasks involve different underlying neural mechanisms, a literature review suggests that both are referred to as emotional memories and that both have been subjected to reconsolidation blockade. The present study uses the same convention, and the term emotional memory refers to both phenomena. In the fear conditioning paradigm, a neutral stimulus, such as a tone (i.e., conditioned stimulus [CS]), is paired with a fear stimulus until presentation of the CS alone elicits the fear response. One day after initial learning, propranolol is administered orally 60–90 minutes before the retrieval of the fear memory. Reactivation of the fear memory is achieved by a single presentation of the CS, (i.e., the reactivation cue) and memory is tested after a drug washout period of 1–7 days. It should be noted that pre- rather than postretrieval propranolol represents a slight departure from the typical reconsolidation protocol; however, in humans this time is required for pharmacological reconsolidation blockers ingested orally to reach their peak bioavailability (for a discussion, see Schiller and Phelps and Brunet and colleagues). A second method of manipulating memory reconsolidation involves script-driven imagery tasks. In one version of this paradigm, participants are asked to write a script detailing an emotionally negative memory. Seven days later, participants receive propranolol or placebo 60–90 minutes before listening to an audiotaped recording of their script, which serves as the reactivation cue. Psychophysiological responses are recorded during this session. After a washout period of 1–7 days, the participants listen to their script while their physiologic responses are recorded, this time without receiving any medication. This final session serves as the test for reconsolidation blockade (see Brunet and colleagues for a variation on this method).

In declarative memory tasks, participants are instructed to learn a list of emotionally valenced and neutral words. At least 24 hours later, they are given propranolol or placebo 60–90 minutes before a cued recall task. A second cued recall task, which serves as the test for reconsolidation blockade, occurs after a washout period of at least 24 hours.

Outcome measures

In the paradigm by Cahill and colleagues, the outcome of interest was the between-group mean difference in long-term memory performance, as measured by free recall of slides or percent correct on a recognition task for the emotional section of the story. In studies using materials other than the slide story (i.e., pictures from the International Affective Pictures System or emotionally valenced word lists), the outcome of interest was between-group difference for recognition memory of negatively valenced pictures or words. In studies whose methods consisted of fear conditioning and script-driven imagery paradigms, physiologic responses (i.e., startle, skin conductance, heart rate) were considered to be measures of fear memory. Neuroimaging studies looking solely at brain activity during memory consolidation and/or reconsolidation were considered to deviate too far from the conventional measurement of memory performance and were thus excluded. For consolidation and reconsolidation studies, we recorded medication dosage, timing, delay before memory testing and sex as possible moderator variables.

Search strategy and data extraction

We searched for articles in PsycINFO, PubMed, ISI Web of Science, Cochrane Central, PILOTS, Google Scholar and www.clinicaltrials.org using the following key words: “propranolol,” “emotion,” “emotional,” “memory,” “consolidation” and “reconsolidation.” The results were exported to a database, and duplicates were removed. Two investigators independently screened the titles and abstracts to exclude irrelevant articles, and they completed independent assessments of all potentially relevant full-text articles. Next, the investigators met to compare results. Discrepancies were resolved by consensus. When consensus could not be achieved, the senior author resolved the disagreement. The reference sections of the included articles were also systematically screened.

Data were extracted by 2 independent reviewers and double-checked by a third party; all disagreements were resolved by consensus. When studies did not report means and standard deviations for standardized between-group differences (i.e., Hedges’ $g$), the following sequence was applied: first, the $t$ test was used to calculate the effect size; second, the data were requested from the authors; and third, for 2 studies effects were estimated from the published figures.

Two investigators independently assessed each study using a quality assessment tool. One point each was given for randomization, double-blind design and description of withdrawals/dropouts. Fourth and fifth points were given if the randomization and blinding methods, respectively, were well described and considered adequate. Studies were required to be double-blind randomized trials and meet at least 1 other quality criterion to be included. Thus, a score of at least 3 out of a possible 5 was deemed acceptable for inclusion. Tables 1 and 2 list the included consolidation and reconsolidation studies, respectively.

Statistical analysis

To examine the between-group difference on memory performance, we opted to use Hedges’ $g$, which produces an adjusted effect size estimate, rather than Cohen’s $d$, because the latter is upwardly biased with small samples. In behavioral studies, Hedges’ $g < 0.2$ represents a small, 0.2–0.5 a moderate and 0.6–0.8 a large effect size. For a few reconsolidation studies, Hedges’ $g$ was averaged across outcomes to control for outcome selection bias. Owing to the moderate number of included studies and methodological heterogeneity, we used a random-effects model to test our hypotheses. We performed homogeneity analyses to identify outliers and sources of heterogeneity using the $Q$ and $I^2$ statistics. To account for the limited number of unpublished studies found, we built a funnel plot to examine publication bias for emotional memory consolidation. Furthermore, we calculated the Rosenthal fail-safe $N$ to determine the number of missing negative studies required.
to nullify our results.39 Publication bias was not assessed for the reconsolidation analysis owing to the limited number of studies included.39 All tests were 2-sided with α < 0.05, unless stated otherwise. We performed our analyses using Comprehensive Meta-Analysis software version 2 (Biostat Inc.).53

**Results**

Figure 1 depicts the study selection process. Twenty experiments from 18 articles were included: 12 pertained to memory consolidation and 8 to reconsolidation. Of the 12 consolidation experiments, 2 were excluded from meta-analysis because they did not report data in a usable format43 or because the data pertained to a clinical sample.7

**Qualitative results**

Table 1 summarizes the characteristics of the memory consolidation studies. Overall, 8 of 12 studies closely followed the paradigm of Cahill and colleagues.21 Of these, 5 studies found that participants treated with propranolol remembered less material than those that were treated with placebo,22,23,25,26,27 and 3 studies28,29,30 failed to find an effect. Of the 4 remaining studies,31,32,33,34 that used different stimuli (emotionally valenced word lists, pictures, fear-conditioning paradigms),28,29,30 found an effect for propranolol.46,48 The last study34 used a script-driven imagery task with healthy participants and failed to find an effect for propranolol. In total, 155 participants received propranolol, and 153 received a closely matched placebo.

The average Jadad score for all included studies was 3.5 on a 5-point scale. The most common reason for losing points was failure to report the exact randomization method or failure to report the dropout rate, which may induce a bias.

**Quantitative results**

**Consolidation analysis**

Figure 2 presents the pooled results for the memory consolidation analysis. Overall, participants treated with propranolol (n = 131) remembered less aversive material than those treated with placebo (n = 128; g = 0.44, 95% confidence interval [CI] 0.14–0.74). Statistical heterogeneity was nonsignificant (Q = 13.56, p = 0.14). Between-study variability was considered low (I² = 33.63%). Sensitivity analyses revealed no outlier. Effect sizes varied between 0 and 1.49. Publication bias analyses revealed a symmetric funnel plot, with only 2 studies missing in order to completely eliminate the publication bias. The Rosenthal fail-safe N analysis indicated that 40 studies with null results would be needed to bring the combined 1-tailed significance to p > 0.05.

**Reconsolidation analysis**

Figure 3 presents the results for the memory reconsolidation analysis. Although heterogeneous (Q = 24.99, p = 0.001, I² = 71.99%), results were significant, and the effect size was large (Hedges g = 0.56, 95% CI 0.13–1.00). Effect sizes ranged

---

**Table 1: Characteristics of included consolidation studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Materials</th>
<th>Participants, propranolol/placebo</th>
<th>Sex, %</th>
<th>Age, mean (SD) [range] yr</th>
<th>Study protocol</th>
<th>Outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cahill et al. 21</td>
<td>Emotional slide story</td>
<td>11:8</td>
<td>Male</td>
<td>27.4 (27.6)</td>
<td>40 mg 60 min before encoding</td>
<td>% recognition story phase 2</td>
</tr>
<tr>
<td>van Stegeren et al. 27</td>
<td>Emotional slide story</td>
<td>14:13</td>
<td>Female</td>
<td>21.4 (2.45)</td>
<td>40 mg 60 min before encoding</td>
<td>% recognition story phase 2</td>
</tr>
<tr>
<td>O’Carroll et al. 29</td>
<td>Emotional slide story</td>
<td>12:12</td>
<td>Undergraduates</td>
<td>44.45 (8.08)</td>
<td>40 mg 60–90 min before encoding</td>
<td>% recognition phase 2</td>
</tr>
<tr>
<td>Reist et al. 37</td>
<td>Emotional slide story</td>
<td>5:5</td>
<td>Male</td>
<td>50.53 (8.5)</td>
<td>40 mg 60–90 min before encoding</td>
<td>% recognition story phase 2</td>
</tr>
<tr>
<td>Reist et al. 38</td>
<td>Emotional slide story</td>
<td>5:4</td>
<td>Female</td>
<td>22.65</td>
<td>40 mg immediately before encoding</td>
<td>% recognition story phase 2</td>
</tr>
<tr>
<td>van Stegeren et al. 27</td>
<td>Emotional slide story</td>
<td>15:15</td>
<td>23</td>
<td>[19–36]</td>
<td>40 mg 65 min before encoding</td>
<td>% free recall story phase 2</td>
</tr>
<tr>
<td>Maheu et al. 35</td>
<td>Emotional slide story</td>
<td>11:13</td>
<td>100</td>
<td>[20–34]</td>
<td>80 mg 90 min before encoding</td>
<td>% free recall story phase 2</td>
</tr>
<tr>
<td>Strange and Dolan 37</td>
<td>Emotionally valenced words</td>
<td>12:12</td>
<td>50</td>
<td>[20–39]</td>
<td>40 mg 90 min before encoding</td>
<td>% recognition word list</td>
</tr>
<tr>
<td>Grillon et al. 38†</td>
<td>Fear conditioning</td>
<td>15:15</td>
<td>46</td>
<td>29 (2.8)</td>
<td>40 mg 60 min before conditioning</td>
<td>Retention fear conditioning</td>
</tr>
<tr>
<td>van Stegeren et al. 27</td>
<td>Emotionally valenced pictures</td>
<td>28:28</td>
<td>50</td>
<td>20.93 (2.38)</td>
<td>80 mg 90 min before encoding</td>
<td>% recognition pictures</td>
</tr>
<tr>
<td>Weymar et al. 44</td>
<td>Emotionally valenced pictures</td>
<td>23:23</td>
<td>100</td>
<td>[19–31]</td>
<td>80 mg 90 min before encoding</td>
<td>% recognition pictures</td>
</tr>
</tbody>
</table>

SD = standard deviation.
†Posttraumatic stress disorder population; data excluded from statistical analysis.
†Data excluded from statistical analysis.
between 0.07 and 1.36. According to the sensitivity analyses, no single study explained the observed heterogeneity. Interestingly, no significant between-group difference emerged when episodic memory retention studies (Hedges $g = 0.58$) were examined separately from studies measuring physiological responses to fear conditioning (Hedges $g = 0.56$; Fig. 4).

Owing to pronounced heterogeneity, we conducted a number of post hoc analyses to determine whether medication dosage, the delay before memory test, or sex$^{45,55}$ moderated the effect size observed in reconsolidation studies. Significant between-group differences were found for all 3 moderators. Studies using 40 mg of propranolol showed a stronger effect that those using 80 mg ($Q_1 = 19.40$, $p < 0.001$), and studies with a 24-hour delay between drug administration and recall demonstrated a larger effect than those with a 1-week period before memory tests ($Q_1 = 6.62$, $p = 0.010$). In addition, studies with male-only samples showed a significantly weaker effect than mixed study samples ($Q_1 = 6.62$, $p = 0.010$). However, these effects should be interpreted with caution since they are all driven by the same 2 studies with null findings.$^{45,56}$

We conducted a meta-regression to further examine the sex effect. No predictive effect was found within studies examining memory consolidation ($z = 0.39$, $p = 0.70$). However, within reconsolidation studies, the greater the proportion of women within a given sample, the larger the effect size ($z = 3.35$, $p = 0.001$).

**Discussion**

Learning under the influence of propranolol led to subsequent recall deficits congruent with consolidation blockade when the stimuli consisted of negatively valenced slides, pictures, word lists and fear-conditioned stimuli. Recall of previously learned material under the influence of propranolol had a similar effect: it led to subsequent recall deficits congruent with consolidation theory when the material consisted of negatively valenced emotional words, or it reduced the expression of previously learned cue-elicited fear responses. In the case of reconsolidation, the evidence is considered less robust, despite the larger effect size, because of the heterogeneity across studies. This result should be interpreted with caution until more studies are published. Finally, the observed effects of propranolol on memory apply to moderately emotional material, as tested in an experimental design with healthy adults. It remains to be determined

---

**Table 2: Characteristics of included reconsolidation studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Materials</th>
<th>Participants, propranolol/placebo</th>
<th>Sex, %</th>
<th>Age, mean (SD) [range] yr</th>
<th>Study protocol</th>
<th>Outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miller et al., unpublished$^*$</td>
<td>Differential fear conditioning</td>
<td>42:25</td>
<td>50 50</td>
<td>25 (4.2)</td>
<td>Day 1: learning; Day 2: propranolol 5 min after reactivation; Day 3: LTM test</td>
<td>Skin conductance response to conditioned stimulus during extinction day 3</td>
</tr>
<tr>
<td>de Quervain et al.$^{46}$</td>
<td>Emotionally valenced word list crossover design</td>
<td>14:14</td>
<td>50 50</td>
<td>23.9 (2.9)</td>
<td>Day 1: learning; Day 2: 40 mg 60 min before LTM test, 2nd LTM test 2 wk later</td>
<td>Free recall number of words</td>
</tr>
<tr>
<td>Kindt et al.$^{47}$</td>
<td>Differential fear conditioning</td>
<td>40:20</td>
<td>28 72</td>
<td>20.7 (2.4)</td>
<td>Day 1: learning; Day 2: 40 mg 90 min before memory reactivation; Day 3: LTM test</td>
<td>Fear potentiated startle to conditioned stimulus during extinction day 3</td>
</tr>
<tr>
<td>Tollenaar et al.$^{48}$</td>
<td>Emotionally valenced word list</td>
<td>27:26</td>
<td>100</td>
<td>20.6 (2.1)</td>
<td>Wk 1: learning; Wk 2: 80 mg 75 min before memory task; Wk 3: memory task</td>
<td>% recognition nouns week 3</td>
</tr>
<tr>
<td>Tollenaar et al.$^{49}$</td>
<td>Script-driven imagery</td>
<td>27:26</td>
<td>100</td>
<td>20.7 (2.2)</td>
<td>Wk 1: script preparation; Wk 2: 80 mg 90 min before memory reactivation; Wk 3: Heart rate and skin conductance response to emotional script</td>
<td>Heart rate and skin conductance response week 3</td>
</tr>
<tr>
<td>Soeter et al.$^{50}$</td>
<td>Differential fear conditioning</td>
<td>40:20</td>
<td>25 75</td>
<td>20.4 (3.8)</td>
<td>Day 1: learning; Day 2: 40 mg 90 min before reactivation; Day 3: LTM test</td>
<td>Fear potentiated startle to conditioned stimulus during extinction day 3</td>
</tr>
<tr>
<td>Kroes et al.$^{51}$</td>
<td>Emotionally valenced word list</td>
<td>12:12</td>
<td>58 42</td>
<td>24.4</td>
<td>Day 1: learning; Day 2: 40 mg 90 min before reactivation; Day 3: LTM test</td>
<td>% free recall day 3</td>
</tr>
<tr>
<td>Schwabe et al.$^{52}$</td>
<td>Emotionally valenced pictures</td>
<td>13:13</td>
<td>50 50</td>
<td>[18–30]</td>
<td>Day 1: learning; Day 2: 40 mg 90 min before reactivation; Day 3: LTM test</td>
<td>% recognition pictures day 3</td>
</tr>
</tbody>
</table>

SD = standard deviation; LTM = long-term memory;

$^*$ Some participants received propranolol with no memory reactivation; these data are excluded from statistical analysis: 19 in Miller et al. (unpublished), 20 in Kindt et al.$^{47}$ and 20 in Soeter et al.$^{50}$
whether more strongly valenced idiosyncratic memories can also be decreased by propranolol (e.g., in clinical populations affected with a mental disorder).

**Underlying mechanisms of memory consolidation and reconsolidation**

There are a number of issues that the present meta-analysis does not address, including the question of the underlying mechanism of the phenomena observed. Although the results are congruent with a consolidation and reconsolidation blockade explanation, other explanations are plausible. Ideally, the propranolol should be given immediately after the memory task (i.e., postretrieval) rather than 60–90 minutes beforehand to eliminate a possible confounding effect of propranolol on memory encoding or retrieval. Importantly, studies administering propranolol immediately before encoding or immediately after (Miller and colleagues, unpublished data, 2004) reactivating the memory failed to find a sustained effect of propranolol. However, this bias is controlled, in principle, by the fact that in studies using the protocol from Cahill and colleagues, the propranolol and placebo groups do not differ on memory performance for the neutral material, suggesting that propranolol does not influence memory encoding more than placebo. In addition, recent data indicates that the memory-impairing effects of propranolol are relatively long-lasting and that propranolol has no effect on brain mechanisms activated during reactivation, ruling out the possibility of an effect solely on retrieval.

**Selection of the emotional material**

Some stimuli may be more susceptible to propranolol-induced amnesia. Because of the limited number of studies currently available for review, a fine-grained analysis taking into consideration the type of stimuli presented could not be performed. However, among the studies reporting negative findings, especially those that did not use the paradigm of Cahill and colleagues, it is possible that the stimuli used were not powerful enough to demonstrate the effect of propranolol in

---

**Fig. 1:** Study selection. *The studies by Reist et al. and Maheu et al. each contain 2 experiments.*

<table>
<thead>
<tr>
<th>Study</th>
<th>No.</th>
<th>Hedges g (SE)</th>
<th>95% CI</th>
<th>Hedges g and 95% CI</th>
<th>Relative weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cahill et al.</td>
<td>19</td>
<td>-1.15 (0.45)</td>
<td>-0.20 to -2.09</td>
<td></td>
<td>7.66</td>
</tr>
<tr>
<td>van Stegeren et al.</td>
<td>27</td>
<td>-1.03 (0.40)</td>
<td>-0.25 to -1.81</td>
<td></td>
<td>9.99</td>
</tr>
<tr>
<td>O’Carroll et al.</td>
<td>24</td>
<td>0.00 (0.39)</td>
<td>0.77 to -0.77</td>
<td></td>
<td>10.15</td>
</tr>
<tr>
<td>Reist et al.</td>
<td>10</td>
<td>-1.49 (0.66)</td>
<td>-0.19 to -2.78</td>
<td></td>
<td>4.61</td>
</tr>
<tr>
<td>van Stegeren et al.</td>
<td>30</td>
<td>0.00 (0.36)</td>
<td>0.70 to -0.70</td>
<td></td>
<td>11.60</td>
</tr>
<tr>
<td>Maheu et al.</td>
<td>24</td>
<td>-0.19 (0.40)</td>
<td>0.59 to -0.96</td>
<td></td>
<td>10.07</td>
</tr>
<tr>
<td>Maheu et al.</td>
<td>27</td>
<td>-0.83 (0.39)</td>
<td>-0.60 to -1.59</td>
<td></td>
<td>10.29</td>
</tr>
<tr>
<td>Strange and Dolan</td>
<td>24</td>
<td>-0.04 (0.39)</td>
<td>0.73 to -0.81</td>
<td></td>
<td>10.15</td>
</tr>
<tr>
<td>van Stegeren et al.</td>
<td>28</td>
<td>-0.54 (0.37)</td>
<td>0.19 to -1.28</td>
<td></td>
<td>10.87</td>
</tr>
<tr>
<td>Weymar et al.</td>
<td>46</td>
<td>-0.08 (0.29)</td>
<td>0.49 to -0.65</td>
<td></td>
<td>14.61</td>
</tr>
<tr>
<td>Total</td>
<td>259</td>
<td>-0.44 (0.15)</td>
<td>-0.14 to -0.74</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.08$, $Q = 13.56$, $p = 0.14$, $I^2 = 33.63\%$.

Test of overall effect: $z = -2.84$, $p < 0.05$.

**Fig. 2:** Propranolol’s effects on emotional memory consolidation. CI = confidence interval; SE = standard error.
blocking consolidation or reconsolidation of negatively valenced emotional material. In other words, in some cases the so-called “emotional” material could have been quite neutral, thus explaining the lack of results in some studies. If some negative findings could be explained by the emotional stimuli not being powerful enough, the effect size reported in our meta-analysis may be a conservative estimate.

Measurement of recall

In contrast to Cahill and colleagues, Strange and Dolan examined propranolol’s effects on long-term recognition memory performance for emotionally valenced word lists. Furthermore, Weymar and colleagues and van Stegeren and colleagues examined emotional memory performance using a set of unrelated pictures. It is unclear whether the non-significant results obtained by Strange and Dolan and by Weymar and colleagues were due in part to the way they measured recall, their use of a set of stimuli very different from that used by Cahill and colleagues, or both.

The way recall is measured may have another type of impact on the results. In the consolidation studies, the most reliable finding seems to be that, compared with the placebo group, participants in the propranolol group failed to recall specific elements of the slides that were accompanied by the emotionally distressing narrative. This is a form of declarative memory. This failure to recall was also reported in 2 of 3 studies looking at reconsolidation, although results from the study by de Quervain and colleagues were not significant. However, in 2 other reconsolidation studies, participants displayed reduced expression of cue-elicited, fear-conditioned physiologic responses (i.e., amygdala-dependent emotional memory), whereas declarative memory remained intact. Future studies will need to explore whether memory reactivation under propranolol decreases the strength of emotional or declarative memory or both and whether this effect is long-lasting.

Medication dosage and sex effects

Most consolidation studies found an effect for propranolol by using a dose of 40 mg. In contrast, Maheu and colleagues did not find significant results using 40 mg of propranolol in a sample of men only. However, 80 mg of propranolol yielded

![Table 3: Propranolol's effects on emotional memory reconsolidation. CI = confidence interval; SE = standard error.](image)

![Table 4: Split-group analysis showing reconsolidation by memory mechanism — fully random effects. CI = confidence interval; SE = standard error.](image)
significant results. Using a fixed low dose of propranolol may not work equally well in all populations because of varying body mass, sex or other reasons. For instance, van Stegeren and colleagues found a significant effect of 80 mg of propranolol on memory performance, but only in women. In parallel, using 80 mg in a male-only sample, Weymar and colleagues did not find an effect of propranolol.

Within the reconsolidation experiments, post hoc analyses revealed a stronger effect for mixed samples using 40 mg of propranolol. In contrast, Tollenaar and colleagues were the only ones to use 80 mg of propranolol in 2 different reconsolidation protocols; both studies involved male-only samples and failed to find significant effects. A sex difference has been found, with women being more influenced by propranolol than men. Three consolidation and 2 reconsolidation studies included in our meta-analysis were conducted with male-only samples; therefore our results potentially underestimate the overall effect size results. Although only observed in the reconsolidation analysis, meta-regression results revealed that the proportion of women significantly predicted the strength of the effect size, lending support to the suggestion that propranolol’s effects may be more pronounced in women than men. Dose effects and sex effects will need to be further explored, also taking into consideration the hormonal cycle of women.

Can propranolol effectively block memory consolidation or reconsolidation in memory-related mental disorders?

The effect of propranolol on memory observed in this meta-analysis applies to moderately negative emotional material, as tested in an experimental design with healthy adults. Propranolol has also shown promise in animals in reducing avoidance conditioning, fear conditioning and craving related to cocaine and nicotine dependence. In humans, Reist and colleagues replicated the paradigm by Cahill and colleagues in both a healthy population and a clinical (PTSD) sample, finding no between-group differences. Although the study by Reist and colleagues did not involve deeply ingrained traumatic memories, propranolol dampened memory enhancement for an emotionally upsetting slide story in both the healthy and clinical populations.

Thus far, 1 small randomized controlled trial used propranolol in a sample of individuals with unremitting PTSD of more than 10 years’ duration in an attempt to decrease the strength of a traumatic memory. In this study, the strength of the trauma memory was lower after a single dose of propranolol than placebo, as measured 1 week later by psychophysiologic responses while listening to audiotaped personal trauma narratives. This study is important because psychophysiologic responding to trauma scripts is the most replicated biological finding in PTSD samples, is less prone to demand characteristics and directly tackles the issue of the strength of the emotional memory. Anecdotally, all the participants of that study retained a declarative memory of their traumatic event. Furthermore, in 3 open-label trials, 1 of which included a control group, Brunet and colleagues demonstrated that 6 treatment sessions with propranolol administered before trauma memory reactivation led to a significant decrease in PTSD symptoms. Propranolol’s capacity to prevent the development of PTSD immediately after trauma exposure has also been examined in a few studies with conflicting findings and methodological flaws.

Further investigations under improved methodological conditions are underway (see clinicaltrials.gov) and should help elucidate this question in the near future.

Limitations

This meta-analysis is limited by the moderate number of studies examining the influence of propranolol on emotional memory consolidation and reconsolidation in healthy adults, making it difficult to examine the effects of moderating variables on outcome. Furthermore, it is noteworthy that most samples consisted entirely of young adults, most commonly undergraduate students, which may limit the ecological validity of results. Finally, in 2 studies, effects had to be estimated from published figures owing to the original data being unavailable. However, removing these studies from our analyses did not change our results.

Conclusion

Pharmacological reconsolidation blockade might have the potential to become a novel treatment in psychiatry. Summarizing the currently available evidence from placebo-controlled experimental studies involving healthy participants, this meta-analysis represents an important step in this direction. In this review, propranolol reduced memory for both new and previously learned emotional material in healthy adults. Future studies will have to test whether more powerful idiosyncratic emotional memories can be durably weakened and whether this weakening can bring about lasting symptomatic relief in various clinical populations that have at their core an emotional memory (e.g., PTSD, phobias, depression, obsessive-compulsive disorder, eating disorders, addictions).

Acknowledgements: A. Brunet holds a salary award from the Fonds de Recherche du Québec - Santé. M.H. Lonergan holds a student award from the Canadian Institutes of Health Research. L.A. Olivera-Figueroa holds a postdoctoral fellowship from the Fernand-Seguin Research Centre.

Competing interests: None declared.

Contributors: All authors contributed to study design, wrote and reviewed the article and approved its publication. M.H. Lonergan, L.A. Olivera-Figueroa and A. Brunet acquired the data, which M.H. Lonergan, R.K. Pitman and A. Brunet analyzed.

References


42. Strange BA, Dolan RJ. Beta-adrenergic modulation of emotional


**JPN’s top viewed articles**

1. How to increase serotonin in the human brain without drugs
   Young

2. L-Tyrosine to alleviate the effects of stress?
   Young
   *J Psychiatry Neurosci* 2007;32(3):224

3. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
   Dean et al.
   *J Psychiatry Neurosci* 2011;36(2):78–86

4. Maternal infection during pregnancy and schizophrenia
   Boksa

5. What is the best treatment for bipolar depression?
   Young

6. Neuroimaging and genetics of borderline personality disorder: a review
   Lis et al.

7. Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology
   Moskowitz and Young

8. Premenstrual dysphoric disorder: burden of illness and treatment guide
   Pearlstein and Steiner

9. Folate and depression — a neglected problem
   Young
   *J Psychiatry Neurosci* 2007;32(3):80–2

10. The long-term impact of treatment with electroconvulsive therapy on discrete memory systems in patients with bipolar disorder
    MacQueen et al.

*Based on page views on PubMed Central of content published in the last 7 years.

Updated June 3, 2013.